Hormographiella aspergillata: an emerging basidiomycete in the clinical setting? A case report and literature review.
Antifungal susceptibility
Basidiomycete
Coprinus cinereus
Fungal colonization
Hormographiella aspergillata
Mould
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
11 Dec 2020
11 Dec 2020
Historique:
received:
31
07
2020
accepted:
02
12
2020
entrez:
14
12
2020
pubmed:
15
12
2020
medline:
8
1
2021
Statut:
epublish
Résumé
Filamentous basidiomycetes are mainly considered to be respiratory tract colonizers but the clinical significance of their isolation in a specimen is debatable. Hormographiella aspergillata was first reported as a human pathogen in 1971. We discuss the role of this mold as a pathogen or colonizer and give an update on diagnostic tools and in vitro antifungal susceptibility. We identified three cases of H. aspergillata with respiratory symptoms in a short period of time. One invasive infection and two colonizations were diagnosed. Culture supernatants showed that H. aspergillata can produce galactomannan and β-D-glucan but not glucuronoxylomannan. For the first time, isavuconazole susceptibility was determined and high minimum inhibitory concentrations (MICs) were found. Liposomal amphotericin B and voriconazole have the lowest MICs. To date, 22 invasive infections involving H. aspergillata have been reported. On isolation of H. aspergillata, its pathogenic potential in clinical settings can be tricky. Molecular identification and antifungal susceptibility testing are essential considering high resistance against several antifungal therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Filamentous basidiomycetes are mainly considered to be respiratory tract colonizers but the clinical significance of their isolation in a specimen is debatable. Hormographiella aspergillata was first reported as a human pathogen in 1971. We discuss the role of this mold as a pathogen or colonizer and give an update on diagnostic tools and in vitro antifungal susceptibility.
CASE PRESENTATION
METHODS
We identified three cases of H. aspergillata with respiratory symptoms in a short period of time. One invasive infection and two colonizations were diagnosed. Culture supernatants showed that H. aspergillata can produce galactomannan and β-D-glucan but not glucuronoxylomannan. For the first time, isavuconazole susceptibility was determined and high minimum inhibitory concentrations (MICs) were found. Liposomal amphotericin B and voriconazole have the lowest MICs.
CONCLUSION
CONCLUSIONS
To date, 22 invasive infections involving H. aspergillata have been reported. On isolation of H. aspergillata, its pathogenic potential in clinical settings can be tricky. Molecular identification and antifungal susceptibility testing are essential considering high resistance against several antifungal therapies.
Identifiants
pubmed: 33308180
doi: 10.1186/s12879-020-05679-z
pii: 10.1186/s12879-020-05679-z
pmc: PMC7731474
doi:
Substances chimiques
Antifungal Agents
0
liposomal amphotericin B
0
Amphotericin B
7XU7A7DROE
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
945Références
J Mycol Med. 2019 Apr;29(1):71-74
pubmed: 30630667
Transpl Infect Dis. 2016 Aug;18(4):611-6
pubmed: 27237466
Microbiology (Reading). 2016 Jul;162(7):1147-1156
pubmed: 27170376
Lab Med. 2019 Oct 10;50(4):426-431
pubmed: 31065690
Antimicrob Agents Chemother. 2013 Jun;57(6):2845-8
pubmed: 23507274
J Med Vet Mycol. 1997 Jan-Feb;35(1):65-9
pubmed: 9061589
Respiration. 2001;68(2):201-3
pubmed: 11287837
Med Mycol. 2016 May;54(4):439-43
pubmed: 26922300
Mycoses. 2015 Jun;58(6):325-36
pubmed: 25808822
J Clin Microbiol. 2011 Jan;49(1):461-5
pubmed: 21068290
New Microbes New Infect. 2017 Dec 05;21:102-104
pubmed: 29541477
Mycopathologia. 2017 Aug;182(7-8):709-713
pubmed: 28144821
Med Mycol. 2002 Apr;40(2):217-9
pubmed: 12058736
Med Mycol. 2014 Nov;52(8):782-97
pubmed: 25202126
J Clin Microbiol. 1997 Oct;35(10):2675-8
pubmed: 9316933
Mycoses. 2015 May;58(5):308-12
pubmed: 25752189
J Clin Microbiol. 2013 Feb;51(2):585-90
pubmed: 23241374
J Med Microbiol. 2005 Jul;54(Pt 7):685-688
pubmed: 15947435
Curr Fungal Infect Rep. 2013 Sep;7(3):219-223
pubmed: 26512308
J Clin Microbiol. 2009 Dec;47(12):4176-9
pubmed: 19846651
J Infect. 2012 Apr;64(4):424-9
pubmed: 22227384
Cardiovasc Pathol. 2008 Sep-Oct;17(5):342-3
pubmed: 18402787
J Med Microbiol. 1971 Aug;4(3):370-4
pubmed: 5116256
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
Clin Microbiol Infect. 2011 Feb;17(2):273-7
pubmed: 20491830
Antonie Van Leeuwenhoek. 1996 Jul;70(1):49-57
pubmed: 8836441
Mycoses. 2013 Nov;56(6):687-9
pubmed: 23672484